Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.
Also called NCT01413204
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 272 participants
- Sponsor
- Registry
-
NCT01413204
-
- Other papers using this trial's data
- Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01413204. Randomized; triple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-08 (actual). Results posted on 2014-06-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TA-7284 Low
- Intervention (Drug)
- TA-7284 High
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct01413204- Content hash
a4a681a68d972f8049ebdf171da81078cdff3dcd4a3e8da1c0a0e1f03977c151